Targeting JAK2 in Myeloproliferative Neoplasms

A discussion ofJAK2-directed therapies, their roles in treatment, and the key clinical trials guiding their use in myeloproliferative neoplasms. Also discussed are some relevant data recently presented at ASCO.

EP. 1: Defining Myeloproliferative Neoplasms

July 14th 2021

Experts discuss the differences between essential thrombocythemia [ET], polycythemia vera [PV], and myelofibrosis [MF] and refinement of diagnosis.

EP. 2: Therapeutic Options for Patients With MPN

July 14th 2021

Dr Verstovsek and Dr Kuykendall discuss the limitations of past treatments for MPNs.

EP. 3: The Role of JAK2 in MPNs

July 14th 2021

A discussion of the role of the JAK2 mutation and other factors in the development of MPNs.

EP. 4: Disease Progression in MPN

July 14th 2021

The progression of disease in MPNs and how genetic testing may inform therapy.

EP. 5: Targeted Therapies for Essential Thrombocythemia

July 21st 2021

Response criteria, quality of life issues, and therapeutic options including ruxolitinib, hydroxyurea, and interferon are discussed in the context of ET.

EP. 6: Individualized Therapy for Low- and High-Risk Patients With MF

July 21st 2021

Additional treatment options for low- and high-risk patients with MPNs are discussed.

EP. 7: Targeted Therapies for Polycythemia Vera

July 21st 2021

Efficacy and safety profiles of therapies for PV are discussed, along with results of the RESPONSE and RESPONSE-2 studies.

EP. 8: Targeted Therapies for Myelofibrosis

July 21st 2021

A discussion of JAK inhibitors, risk models, quality of life, splenomegaly, and other issues in treating patients with MF.

EP. 9: Alternative Dosing and JAK Inhibitors in the Second-Line Setting

July 28th 2021

Alternative dosing schedules and the use of JAK inhibitors for patients with MPNs in the second-line setting are explored.

EP. 10: Ongoing Studies and Combination Therapy in MPNs

July 28th 2021

Combination trials and new agents for MPNs, such as parsaclisib and momelotinib, are discussed in the context of recent ASCO presentations.